Your location：Home page > Program
Print Program-at-a-Glance List of Speakers/Chairs
Search：
All Dates (UTC+8)：
  • All
  • 2024-06-06 [Thursday]
  • 2024-06-07 [Friday]
  • 2024-06-08 [Saturday]
All Rooms：
  • All
  • Watson Auditorium
  • Exhibition Area - II
  • Exhibition Area - III
  • Meeting room - M1
  • Meeting Room - M2
  • Meeting Room - M3
  • Meeing Room-M4
  • Meeting Room - M5
  • Meeting room - M9

2024-06-07 Friday

Exhibition Area - III (UTC+8)

12:15-13:15 (UTC+8) | Art of Interventional Therapy for Liver Cancer
Moderator：
Zhi-Ping Yan Zhongshan Hospital, Fudan University, China 丨 Hai-Liang Li Henan Cancer Hospital, China
Beijing Time (UTC+8) Presentation Topic Speaker Affiliation / Organization
12:15-12:20

Opening Remarks

Gao-Jun Teng Zhongda Hospital, Southeast University, China
12:20-12:35

TACE with epirubicin-loaded microspheres for HCC: A prospective, single-arm, multicenter, phase 2 study (STOPPER trial)

 Hai-Dong Zhu Zhongda Hospital, Southeast University, China
12:35-12:45

Efficacy & Safety of TANDEM Microspheres in Super-selective Transarterial Chemoembolization

 David Hahn
12:45-12:55

Redefining the Precision Image-guided Solution for Interventional Oncology in Liver Cancer Treatment

 Simone Henrichs
12:55-13:15

Panel Discussion

Ming Chao The Second Affiliated Hospital of Zhejiang University Medical College, China / Xu Zhu Beijing Cancer Hospital, China
13:30-14:40 (UTC+8) | Current Status and Future Synergistic Opportunities: Interventional Oncology and Immuno-oncology for Primary Liver Cancer I
Moderator：
Edward W. Lee David Geffen School of Medicine at UCLA, USA 丨 Jian Zhou Zhongshan Hospital, Fudan University, China
Beijing Time (UTC+8) Presentation Topic Speaker Affiliation / Organization
13:30-13:42

MDT strategy for management of primary liver cancer

 Ming Kuang The First Affiliated Hospital, Sun Yat-Sen University, China
13:42-13:54

Personalized treatment for HCC – different tumors, different treatments

 Edward W. Lee David Geffen School of Medicine at UCLA, USA
13:54-14:06

Current status of HCC management in South Korea

 Hyun Ki Yoon Asan Medical Center, University of Ulsan College of Medicine, Korea
14:06-14:18

All about extrahepatic collaterals in TACE for HCCs

 Sangjoon Park Catholic Kwandong University College of Medicine, International St. Mary's Hospital, Korea
14:18-14:30

Chinese Expert Consensus on Conversion and Perioperative Management of Hepatocellular Carcinoma(HCC)

 Jian Zhou Zhongshan Hospital, Fudan University, China
14:30-14:40

Q & A
14:40-16:00 (UTC+8) | Current Status and Future Synergistic Opportunities: Interventional Oncology and Immuno-oncology for Primary Liver Cancer II
Moderator：
George Lau Humanity and Health Medical Group, HKSAR, China 丨 Ren-Jie Yang Peking University Cancer Hospital, China
Beijing Time (UTC+8) Presentation Topic Speaker Affiliation / Organization
14:40-14:52

Pressure-enabled delivery and the future of locoregional immunotherapy

 Jon C. Davidson University Hospitals Cleveland Medical Center, USA
14:52-15:04

The dynamic of T cell responses correlated with the anti-PD-1 adjuvant therapy after RFA for patients with HCC

 Yong-Hong Zhang Beijing YouAn Hospital, Capital Medical University, China
15:04-15:16

Establishing and harmonizing systemic and locoregional therapy in HCC

 David M. Liu Vancouver General Hospital, Canada
15:16-15:28

Immunotherapy for hepatocellular carcinoma

 George Lau Humanity and Health Medical Group, HKSAR, China
15:28-15:40

The role of TACE vs DEB-TACE in treating HCC: Do we need elution?

 Ziv J. Haskal University of Virginia School of Medicine, USA
15:40-16:00

Q&A
16:00-17:00 (UTC+8) | Managing a Long and Winding Road: Liver Metastases
Moderator：
Eduardo Houghton University of Buenos Aires, Argentina 丨 Lian-Xin Liu The First Affiliated Hospital of University of Science and Technology of China, China
Beijing Time (UTC+8) Presentation Topic Speaker Affiliation / Organization
16:00-16:12

Percutaneous liver tumors ablation: Current indications and evidence

 Eduardo Houghton University of Buenos Aires, Argentina
16:12-16:24

ctDNA Test Application in MRD for Colorectal Cancer

 Gong Chen Sun Yat-sen University Cancer Center, China
16:24-16:36

DSM transarterial chemosaturation vs DEB TACE in liver metastases: Which works best?

 Alex Tang Ah Lak Subang Jaya Medical Centre, Malaysia
16:36-16:48

Chemoembolization in mCRC

 Roberto Iezzi Università Cattolica del Sacro Cuore, Italy
16:48-17:00

DEBIRI combined with HAIC for colorectal cancer liver metastases

 Xu Zhu Beijing Cancer Hospital, China
17:00-18:10 (UTC+8) | Shaping the Future of Ablation for Solid Tumors
Moderator：
Min Woo Lee Samsung Medical Center, Korea 丨 Jie Yu Chinese PLA General Hospital, China
Beijing Time (UTC+8) Presentation Topic Speaker Affiliation / Organization
17:00-17:12

The standard and consensus of thermal ablation for thyroid nodules

 Dong Xu Zhejiang Cancer Hospital, China
17:12-17:24

Treating HCC with cryoablation

 Min Woo Lee Samsung Medical Center, Korea
17:24-17:36

Ultrasound guided microwave ablation for adenomyosis of the uterus

 Hui-Xiong Xu Zhongshan Hospital，Fudan University, China
17:36-17:48

Different energy ablation in tumor treatment

 Yue-Yong Xiao The First Medical Center of Chinese PLA General Hospital, China
17:48-18:00

Ultrasound-guided ablation for liver cancer

 Xiao-Yan Xie First Affiliated Hospital of Sun Yat-sen University, China
18:00-18:10

Q ＆ A
Conference Admin